news, journals and articles from all over the world.
Professor Sir John Pendry, an HKIAS Senior Fellow and a distinguished figure in physics known for his pioneering work on metamaterials, visited City University of Hong Kong (CityUHK) from October 20 to October 26, 2024. His visit featured a series of engaging sessions and lectures.
Digital Science is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having on academics and their institutions.
Varda Space Industries, Inc., the world’s first in-space pharmaceutical processing and hypersonic Earth re-entry logistics company, together with SSPC, the Research Ireland Centre for Pharmaceuticals, today announced a research collaboration that aims to advance mathematical modeling of crystallization in microgravity, the first such framework that considers polymorphism.
Social Research Institute, Chulalongkorn University, signed an MOU with Yunus Centre, the world’s leading organization in social development. This MOU aims to pave the way for further collaboration and foster the “power of change” to drive Thai society toward a sustainable future. This collaboration will focus on combining the knowledge, experience, and resources of both organizations in projects and activities.
Developing nations need greater visibility, acknowledgement and support for their research into the United Nations’ Sustainable Development Goals (SDGs), according to the authors of a major analysis of the past 15 years of worldwide research into SDGs.
Cloud-based software company Overleaf has reached 10 million users in 189 countries around the world, thanks to strong and sustained user growth among university academics, students, research institutions and industry.
Researchers at Rutgers Cancer Institute of New Jersey, Rutgers New Jersey Medical School (NJMS) and the Center for Theoretical Biological Physics (CTBP) at Rice University in Houston, Texas, have demonstrated that a technology with favorable biological attributes known as phage display could be a viable platform for the development of new vaccines to protect against COVID-19.
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
On Wednesday in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu